MSD has received the UK MHRA approval for sotatercept, marketed as Winrevair, to treat PAH in the adult population.

KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.

HUTCHMED (China) has entered into agreements to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals (SHPL) ...

Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that ...

Innovent and Roche have entered a partnership and exclusive licence agreement to accelerate the development of IBI3009.

Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

Coronavirus Disease 2019 (COVID-19) vaccine 2 is under clinical development by Sinopharm Group and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

Rifaximin is under clinical development by Nexpharm Korea and currently in Phase I for Irritable Bowel Syndrome.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

Oxime/Methoxime is under clinical development by Bodor Laboratories and currently in Phase II for Unspecified Ophthalmological Disorders.